Double-blind Comparison of etodolac and diclofenac in patients Mith rheumatoid arthritis

Abstract

The efficacy and tolerability of etodolac was compared to diclofenac in a multi-centre, double-blind, randomized parallel group study. Fifty-three patients with rheumatoid arthritis received etodolac (400 mg/day) and 55 patients received diclofenac (150 mg/day) for 12 weeks. Thirty-nine etodolac-treated patients and 44 diclofenac-treated patients completed the study. At the final evaluation, etodolac-treated patients showed significant (p < or = 0.05) improvement for all 4 primary assessments (patients' and physicians' global evaluations, number of tender or painful joints, and number of swollen joints) and 6 of 7 secondary assessments, while diclofenac-treated patients showed significant improvement for 3 primary assessments (patients' and physicians' global evaluations and number of tender joints) and 3 secondary assessments. In the physicians' global assessment, improvement at the final evaluation was indicated for 58% of the etodolac-treated patients and 47% of the diclofenac-treated patients. Both etodolac and diclofenac were well tolerated. As expected for non-steroidal anti-inflammatory drugs, gastrointestinal side-effects were the most common, occurring in 12 patients in each group. There were no significant differences between groups in the incidence of any study event. In conclusion, the results of this study indicate that etodolac is well tolerated and effective in the treatment of rheumatoid arthritis, comparable to diclofenac.

Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee

“…Some of the clinical trials also used diclofenac as comparator. The findings were universal that both etodolac and diclofenac showed comparable pain-relieving effect and tolerability 3,8,10 . In addition, although the incidence rate varied in previous studies, gastrointestinal symptoms were the most common drugrelated adverse events observed 10 .…”

“…The findings were universal that both etodolac and diclofenac showed comparable pain-relieving effect and tolerability 3,8,10 . In addition, although the incidence rate varied in previous studies, gastrointestinal symptoms were the most common drugrelated adverse events observed 10 . Similar to the present study, there was a statistically significant difference between the etodolac and diclofenac treatment groups for changes in SGPT value (-1.3 U/L and +11.2 U/L, respectively) observed in one previous study.…”

“…Etodolac has been widely compared to other conventional NSAIDs in treating osteoarthritis of the knee 2,3,5,6,8,9,10 . Some of the clinical trials also used diclofenac as comparator.…”

Nonsteroidal anti-inflammatory drugs as adjuvant analgesics in cancer patients

“…17 ) No suppression occurred with either SC58125 and SC-236, the COX-2-selective agents studied. To date, human studies involving relative COX-2 selective agents have shown efficacy in rheumatoid 18,19 and osteoarthritic pain 20,21 and in acute dental pain 22 areas where there is a strong peripheral and inflammatory component to the pain, but they have not been studied in areas of pain where central mechanisms predominate.…”

Etodolac, a Well Known and Actively Used Drug in Different Countries of the World. Would It Be Time for Us?

“…Так, высокий терапевтический потенциал этодолака при РА демонстрирует работа G. Lonauer и соавт. [29]. В ходе РКИ проводилось сравнение этого препарата в дозе 800 мг/сут и диклофенака 150 мг/сут у 108 больных РА.…”